In the BioHarmony Drug Report Database

"Preview" Icon

Lenalidomide

Revlimid (lenalidomide) is a small molecule pharmaceutical. Lenalidomide was first approved as Revlimid on 2005-12-27. It is used to treat b-cell lymphoma marginal zone, follicular lymphoma, mantle-cell lymphoma, multiple myeloma, and myelodysplastic syndromes in the USA. It has been approved in Europe to treat follicular lymphoma, mantle-cell lymphoma, multiple myeloma, and myelodysplastic syndromes. The pharmaceutical is active against protein cereblon. Revlimid’s patents are valid until 2028-03-08 (FDA).

 

Trade Name

 

Revlimid
 

Common Name

 

lenalidomide
 

ChEMBL ID

 

CHEMBL848
 

Indication

 

b-cell lymphoma marginal zone, follicular lymphoma, mantle-cell lymphoma, multiple myeloma, myelodysplastic syndromes
 

Drug Class

 

Thalidomide derivatives; narcotic agonists/antagonists (normorphine type)

Image (chem structure or protein)

Lenalidomide structure rendering